Document:

Exhibit 10.20

 

THIS WARRANT AND THE SECURITIES ISSUABLE
UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF,
AND MAY NOT BE SOLD, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT AND SUCH STATE SECURITIES LAWS.

 

VOID AFTER 5:00 P.M. ON NOVEMBER 1, 2023

 

TO PHARMACEUTICALS LLC

 

WARRANT TO PURCHASE UNITS

 

New York, New
York

Certificate
No. 2

 

THIS IS TO CERTIFY
THAT, for value received, Bernard Sucher, an individual residing at 715 Sevilla Avenue, Coral Gables, Florida 33134-5627 (the “Warrantholder”),
is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from TO Pharmaceuticals
LLC, a Delaware limited liability (the “Company”), up to 5,593 Class A Units (the “Warrant Units”) of the
Company (“Units”), at an exercise price equal to $15.11 per Unit (the “Exercise Price”) at the times and
in the manner set forth below.

 

As provided herein,
the Exercise Price and the number of Warrant Units which may be purchased upon the exercise of this Warrant are, upon the happening
of certain events, subject to modification and adjustment.

 

The rights of the registered
holder of this Warrant shall be subject to the following further terms and conditions:

 

		1.	Exercise of Warrant; Payment of Exercise Price.

 

		(a)	Exercise of Warrant.

 

(i)       While
this Warrant remains outstanding, this Warrant shall be fully exercisable, in whole or in part, as of the date hereof (the “Exercisability
Date”), upon submission by the Warrantholder to the Company of the exercise form attached as Exhibit A hereto (the
“Exercise Form”) duly executed by the Warrantholder or by the Warrantholder’s duly authorized attorney-in-fact,
at the principal office of the Company, or at such other office or agency in the United States as the Company may designate by
notice in writing to the Warrantholder (in either event, the “Company Offices”), accompanied by payment in accordance
with Section 1(b), of the aggregate Exercise Price payable for the Warrant Units being purchased. If the Warrantholder exercises
the Warrant for fewer than all of the Warrant Units issuable in accordance with this Warrant, the Company shall, upon each exercise
prior to the Expiration Date, execute and deliver to the Warrantholder a new Warrant (dated as of the date hereof) evidencing the
balance of the Units that remain subject to issuance upon the exercise of this Warrant. This Warrant shall expire on the fifth
(5th) anniversary of the date hereof (the “Expiration Date”), and thereupon the Warrantholder shall surrender
this Warrant.

 

    	 	1	 

     

    

  

(ii)       On
the date of exercise of this Warrant, upon the Warrantholder exercising the same in compliance with the terms hereof, and if previous
to such exercise the Warrantholder is not a party to the operating agreement of the Company, upon the execution and delivery to
the Company of the joinder agreement in the form attached hereto as Exhibit B, the Warrantholder shall be deemed to have
become the holder of record for all purposes of the Units to which the exercise relates.

 

(iii)       As
soon as practicable after the exercise of all or part of this Warrant, the Company, at its expense (including the payment by it
of any applicable issue taxes), will cause to be issued in the name of and delivered to the Warrantholder a certificate or certificates
evidencing the number of duly authorized, validly issued, fully paid and nonassessable Units to which the Warrantholder shall be
entitled upon such exercise, if the units of membership interests of the Company are certificated as of such time.

 

(b)          Payment
of Exercise Price. Payment of the Exercise Price shall be made, at the option of the Warrantholder as expressed in the Exercise
Form, by the following methods:

 

(i)        by
delivery to the Company of a certified or official bank check payable to the order of the Company or by wire transfer of immediately
available funds to an account designated in writing by the Company, in the amount of such aggregate Exercise Price for Warrant
Units being purchased hereunder;

 

(ii)       by
instructing the Company to withhold a number of Warrant Units then issuable upon exercise of this Warrant with an aggregate fair
market value (“Fair Market Value”), as determined in good faith by the Board of Managers of the Company as of the Exercise
Date, equal to the aggregate Exercise Price for Warrant Units being purchased hereunder;

 

(iii)      by
surrendering to the Company (x) Warrant Units previously acquired by the Warrantholder with an aggregate Fair Market Value as of
the Exercise Date equal to the aggregate Exercise Price for Warrant Units being purchased hereunder and/or (y) other securities
of the Company having a value as of the Exercise Date equal to the aggregate Exercise Price for Warrant Units being purchased hereunder
(which value in the case of debt securities shall be the principal amount thereof plus accrued and unpaid interest, in the case
of preferred units shall be the liquidation value thereof plus accumulated and unpaid distributions, and in the case of Units shall
be the Fair Market Value thereof); or

 

(iv)      any
combination of the foregoing.

 

In the event of any withholding of Warrant
Units or surrender of other equity securities pursuant to clause (b)(ii) or (iii) above where the number of Units whose value is
equal to the aggregate Exercise Price is not a whole number, the number of Units withheld by or surrendered to the Company shall
be rounded up to the nearest whole Unit and the Company shall make a cash payment to the Warrantholder (by delivery of a certified
or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of a Unit being so
withheld by or surrendered to the Company in an amount equal to the product of (x) such incremental fraction of a Unit being so
withheld or surrendered multiplied by (y) in the case of Units, the Fair Market Value per Warrant Unit as of the Exercise Date,
and, in all other cases, the value thereof as of the Exercise Date determined in accordance with clause (iii)(y) above.

 

		2.	Issuance of Units; Reservation of Units.

 

(a)          The
Company covenants and agrees that all Units which may be issued upon the exercise of all or part of this Warrant will, upon issuance
in accordance with the terms hereof, be validly issued and free from all taxes, liens and charges with respect to the issue thereof.

 

(b)          The
Company further covenants and agrees that if any Units to be reserved for the purpose of the issuance of Units upon the exercise
of this Warrant require registration with, or approval of, any governmental authority under any federal or state law before such
Units may be validly issued or delivered upon exercise, then the Company will promptly use its best efforts to effect such registration
or obtain such approval, as the case may be.

 

    	 	2	 

     

    

  

		3.	Adjustments of Exercise Price, Number and Character
of Warrant Units, and Number of Warrants.

 

The Exercise Price and
the number and kind of securities purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time
upon the happening of the events enumerated in this Section 3.

 

(a)          Distributions,
Subdivisions and Combinations. In case the Company shall at any time on or before the Expiration Date:

 

(i)         pay
or make a distribution in Units or other securities of the Company to holders of all its outstanding Units;

 

(ii)        subdivide
or reclassify the outstanding Units into a greater number of Units;

 

(iii)       combine
the outstanding Units into a smaller number of Units; or

 

(iv)       issue
by reclassification of its Units other securities of the Company (including any such reclassification in connection with a consolidation
or merger in which the Company is the continuing corporation),

 

then the number and kind of securities
purchasable upon exercise of this Warrant outstanding immediately prior thereto shall be adjusted so that the Warrantholder shall
be entitled to receive the kind and number of Units or other securities of the Company which the Warrantholder would have owned
or have been entitled to receive after the happening of any of the events described above had this Warrant been exercised in full
immediately prior to the earlier of the happening of such event or any record date in respect thereto. In the event of any adjustment
of the number of Units or other securities of the Company purchasable upon the exercise of this Warrant pursuant to this Paragraph
3(a), the Exercise Price shall be adjusted to be the amount resulting from dividing the number of Units (including fractional Units)
covered by this Warrant immediately after such adjustment into the total amount payable upon exercise of this Warrant in full immediately
prior to such adjustment. An adjustment made pursuant to this Paragraph 3(a) shall become effective immediately after the effective
date of such event retroactive to the record date for any such event. Such adjustment shall be made successively whenever any event
listed above shall occur.

 

(b)          Extraordinary
Distributions.

 

(i)       In
case the Company shall at any time on or before the Expiration Date fix a record date for the issuance of rights, options, or warrants
to all holders of its outstanding Units, entitling them (for a period expiring within 45 days after such record date) to subscribe
for or purchase Units (or securities exchangeable for or convertible into Units) at a price per Unit (or having an exchange or
conversion price per Unit, with respect to a security exchangeable for or convertible into Units) which is lower than the current
Exercise Price per Unit (as defined in Paragraph 3(d) below) on such record date, then the Exercise Price shall be adjusted by
multiplying the Exercise Price in effect immediately prior to such record date by a fraction, of which (i) the numerator shall
be the number of Units outstanding on such record date plus the number of Units which the aggregate offering price of the
total number of Units so to be offered (or the aggregate initial exchange or conversion price of the exchangeable or convertible
securities so to be offered) would purchase at such current Exercise Price and (ii) the denominator shall be the number of Units
outstanding on such record date plus the number of additional Units to be offered for subscription or purchase (or into which the
exchangeable or convertible securities so to be offered are initially exchangeable or convertible). Such adjustment shall become
effective at the close of business on such record date; however, to the extent that Units (or securities exchangeable for or convertible
into Units) are not delivered after the expiration of such rights, options, or warrants, the Exercise Price shall be readjusted
(but only with respect to any portion of this Warrant exercised after such expiration) to the Exercise Price which would then be
in effect had the adjustments made upon the issuance of such rights, options, or warrants been made upon the basis of delivery
of only the number of Units (or securities exchangeable for or convertible into Units) actually issued. In case any subscription
price may be paid in a consideration part or all of which shall be in a form other than cash, the value of such consideration shall
be as determined in good faith by the Board of Managers of the Company and shall be described in a statement mailed to the Warrantholder.
Units owned by or held for the account of the Company shall not be deemed outstanding for the purpose of any such computation.

 

    	 	3	 

     

    

  

(ii)       In
case the Company shall at any time after the original date of issuance of this Warrant distribute to all holders of its Units (including
any such distribution made in connection with a consolidation or merger in which the Company is the surviving corporation) evidences
of its indebtedness or assets (excluding distributions payable out of consolidated net income or earned surplus in accordance with
New York law and distributions payable in Units described in Paragraph 3(a) above) or rights, options, or warrants or exchangeable
or convertible securities containing the right to subscribe for or purchase Units (or securities exchangeable for or convertible
into Units), then the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record
date for such distribution by a fraction, of which (i) the numerator shall be the current Exercise Price per Unit of the portion
of the evidences of indebtedness or assets so to be distributed or of such rights, options or warrants applicable to one Unit and
(ii) the denominator shall be such current Exercise Price per Unit. Such adjustment shall be made whenever any such distribution
is made, and shall become effective on the date of distribution retroactive to the record date for such transaction.

 

(c)          Minimum
Adjustment. Except as hereinafter provided, no adjustment of the Exercise Price hereunder shall be made if such adjustment
results in a change of the Exercise Price then in effect of less than one dollar ($1.00) per Unit. Any adjustment of less than
one dollar ($1.00) per Unit of any Exercise Price shall be carried forward and shall be made at the time of and together with any
subsequent adjustment which, together with adjustment or adjustments so carried forward, amounts to one dollar ($1.00) per Unit
or more. However, upon exercise of this Warrant, the Company shall make all necessary adjustments (to the nearest cent) not theretofore
made to the Exercise Price up to and including the effective date upon which this Warrant is exercised.

 

(d)          Notice
of Adjustments. Whenever the Exercise Price shall be adjusted pursuant to this Section 3, the Company shall promptly deliver
a certificate signed by the Chief Executive Officer, President or a Vice President and by the Chief Financial Officer, Treasurer
or an Assistant Treasurer or the Secretary or an Assistant Secretary of the Company, setting forth, in reasonable detail, the event
requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated (including a description
of the basis on which the Board of Managers of the Company made any determination hereunder), in accordance with the provisions
of Section 8 hereof.

 

(e)          Capital
Reorganizations and Other Reclassifications. In case of any capital reorganization of the Company, or of any reclassification
of the Units (other than a reclassification, subdivision or combination of Units referred to in Paragraph 3(a)), this Warrant shall,
after such capital reorganization, reclassification of Units, consolidation, merger, or sale, be immediately exercisable, upon
the terms and conditions specified in this Warrant, for the kind, amount and number of Units or other securities, assets, or cash
to which a holder of the number of Units purchasable (at the time of such capital reorganization, reclassification of Units, consolidation,
merger or sale) upon exercise of this Warrant would have been entitled to receive upon such capital reorganization, reclassification
of Units, consolidation, merger, or sale; and in any such case, if necessary, the provisions set forth in this Section 3 with respect
to the rights and interests thereafter of the Warrantholder shall be appropriately adjusted so as to be applicable, as nearly equivalent
as possible, to any Units or other securities, assets, or cash thereafter deliverable on the exercise of this Warrant. The Company
shall not effect any such consolidation, merger, or sale, unless prior to or simultaneously with the consummation thereof the successor
corporation or entity (if other than the Company) resulting from such consolidation or merger or the corporation or entity purchasing
such assets or other appropriate corporation or entity shall assume, by written instrument, the obligation to deliver to the Warrantholder
such Units, securities, assets, or cash as, in accordance with the foregoing provisions, such holders may be entitled to purchase
and the other obligations hereunder. The subdivision or combination of Units at any time outstanding into a greater or lesser number
of Units shall not be deemed to be a reclassification of the Units for purposes of this Paragraph 3(f).

 

    	 	4	 

     

    

  

(f)          Adjustments
to Other Securities. In the event that at any time, as a result of an adjustment made pursuant to this Section 3, the Warrantholder
shall become entitled to purchase any Units or securities of the Company other than the Units, thereafter the number of such other
Units or securities so purchasable upon exercise of each Warrant and the exercise price for such Units or securities shall be subject
to adjustment from time to time in a manner and on terms as nearly equivalent as possible to the provisions with respect to the
Units contained in Paragraphs 3(a) through (c), inclusive.

 

(g)          Deferral
of Issuance of Additional Units in Certain Circumstances. In any case in which this Section 3 shall require that an adjustment
in the Exercise Price be made effective as of a record date for a specified event, the Company may elect to defer until the occurrence
of such event issuing to the Warrantholder exercised after such record date the Units, if any, issuable upon such exercise over
and above the Units, if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such adjustment;
provided, however, that the Company shall deliver as soon as practicable to such holder a due bill or other appropriate
instrument provided by the Company evidencing such holder’s right to receive such additional Units upon the occurrence of
the event requiring such adjustment.

 

4.            Replacement
of Securities. If this Warrant shall be lost, stolen, mutilated or destroyed, the Company shall, on such terms as to indemnity
or otherwise as the Company may in its discretion reasonably impose, issue a new warrant of like tenor or date representing in
the aggregate the right to subscribe for and purchase the number of Units which may be subscribed for and purchased hereunder.
Any such new warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen,
mutilated or destroyed warrant shall be at any time enforceable by anyone.

 

5.            Registration.
This Warrant shall be numbered and shall be registered in a register (the “Warrant Register”) maintained at the offices
of the Company as they are issued. The Warrant Register shall list the name, address and Social Security or other Federal Identification
Number, if any, of all warrantholders. The Company shall be entitled to treat the Warrantholder as set forth in the Warrant Register
as the owner in fact of this Warrant as set forth therein for all purposes and shall not be bound to recognize any equitable or
other claim to or interest in this Warrant on the part of any other person, and shall not be liable for any registration or transfer
of this Warrant that is registered or to be registered in the name of a fiduciary or the nominee of a fiduciary unless made with
the actual knowledge that a fiduciary or nominee is committing a breach of trust in requesting such registration of transfer, or
with such knowledge of such facts that its participation therein amounts to bad faith.

 

6.            Transfer.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED. THIS WARRANT HAS BEEN ACQUIRED, AND ANY UNITS OR ANY OTHER SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT
ARE REQUIRED TO BE ACQUIRED, FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE SOLD, ASSIGNED,
PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR THIS WARRANT AND/OR SUCH UNITS OR
OTHER SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY
TO THE ISSUER OF THIS WARRANT AND SUCH UNITS OR OTHER SECURITIES TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT
AND SUCH STATE SECURITIES LAWS.

 

    	 	5	 

     

    

  

7.            Exchange
of Warrant. This Warrant may be exchanged for another warrant entitling the Warrantholder thereof to purchase a like aggregate
number of Units as this Warrant entitles such Warrantholder to purchase. A Warrantholder desiring to so exchange this Warrant shall
make such request in writing delivered to the Company, and shall surrender this Warrant therewith. Thereupon, the Company shall
execute and deliver to the person entitled thereto a new warrant or warrants, as the case may be, as so requested.

 

8.            Notices.
All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified
mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed:

 

If to the
Company:

 

TO PHARMACEUTICALS
LLC

77 Water
Street, 8th Floor

New York,
New York 10005

Email: seth@katanassociates.com

Attention:
CEO

 

With a copy
to:

Kaufman &
Associates, LLC

190 Motor
Parkway, Suite 202

Hauppauge,
New York 11788

Telephone:
(631) 972-0042

Facsimile:
(631) 410-1007

Attention:
Neil M. Kaufman

Email: nkaufman@kaufman-associates.com

 

If to the
Warrantholder:

 

Bernard Sucher

715 Sevilla
Avenue

Coral Gables,
Florida 33134-5627

Email: bernie@tikunolam.com

 

Each such notice or other communication
shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger
or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying
next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of
its receipt or five (5) days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United
States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer, if
sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s
next business day, or (iv) if sent via electronic mail, upon its delivery, if sent during normal business hours of the recipient,
or if not sent during normal business hours of the recipient, then on the recipient’s next business day.

 

    	 	6	 

     

    

  

9.            Miscellaneous.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination is sought. This Warrant is deemed to have been
delivered in the State of New York and shall be construed and enforced in accordance with and governed by the laws of such State,
without regard to its conflicts of laws principles. The headings in this Warrant are for purposes of reference only, and shall
not limit or otherwise affect any of the terms hereof.

 

10.          Expiration.
Unless as hereinafter provided, the right to exercise this Warrant shall expire at the Expiration Date.

 

[Signature Page Follows]

 

    	 	7	 

     

    

  

Dated:  November 1, 2018

 

	 	TO PHARMACEUTICALS LLC
	 	 	 
	 	By:	/s/ Seth Yakatan
	 	 	Seth Yakatan
	 	 	Chief Executive Officer

 

    	 	8	 

     

    

 

EXHIBIT A

EXERCISE FORM

 

	 	Dated:___________________________

 

TO: TO PHARMACEUTICALS LLC:

 

The undersigned hereby
irrevocably elects to exercise the within Warrant, to the extent of purchasing _____________ Units, and hereby makes payment of
the Exercise Price in payment of the actual Exercise Price therefor as follows:

 

 ̈$___________________
by certified or official bank check payable to the order of the Company or by wire transfer.

 

 ̈$________________
by withholding Warrant Units issuable upon exercise of this Warrant;

 

 ̈$_____________
by surrendering to the Company (x) $__________ for Warrant Units previously acquired by the Warrantholder, and/or (y)
$_______ for other securities of the Company.

 

INSTRUCTIONS FOR REGISTRATION OF UNITS

 

	Name:	 	 
	 	 	(Please type or print in block letters)
	Taxpayer Identification Number:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Signature:	 	 
	 	 	(Signature must conform in all respects to the name of the Warrantholder as set forth on the face of this Warrant)

 

    	 	9	 

     

    

 

EXHIBIT B

JOINDER TO 

 

OPERATING AGREEMENT

 

This JOINDER
(the “Joinder”) to the Amended and Restated Operating Agreement of TO Pharmaceuticals LLC, a Delaware limited
liability company (the “Company”), dated as of July 13, 2018, as amended or restated from time to time (the
“Agreement”), is made and entered into as of the date below, by and between the Company and the undersigned
(“Holder”). Capitalized terms used herein but not otherwise defined shall have the meanings set forth in the
Agreement.

 

WHEREAS, on
the date hereof, Holder has acquired ______ Class A Units and the Agreement and the Company require Holder, as a holder of such
Interest, to become a party to the Agreement, and Holder agrees to do so in accordance with the terms hereof.

 

NOW, THEREFORE,
in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties to this Joinder hereby agree as follows:

 

		A.	Agreement to be Bound. Holder hereby (i) acknowledges that he/she/it has
                                                                received and reviewed a complete copy of the Agreement and (ii) agrees that upon execution of this Joinder, he/she/it shall
                                                                become a party to the Agreement and shall be fully bound by, and subject to, all of the covenants, terms and conditions of
                                                                the Agreement as though an original party thereto and shall be deemed, and is hereby admitted as, a Member for all purposes
                                                                thereof and entitled to all the rights incidental thereto.

 

		B.	Members Schedule. For purposes of Exhibit A to the Agreement, the name, address,
capital account, Allocation Percentages and number of Membership Units of the Holder are as follows:

 

	Name of Member	 	Capital	 	Allocation	 	 	Membership	 
	and Address	 	Account	 	Percentage	 	 	Units	 
	[________________]	 	$	________	 	__	%	 	[_____]	 

 

		C.	Governing Law. This Agreement and the rights of the parties hereunder shall be interpreted
in accordance with the laws of the State of Delaware, and all rights and remedies shall be governed by such laws without regard
to principles of conflicts of laws.

 

		D.	Counterparts. This Joinder may be executed in multiple counterparts (and may be transmitted
via facsimile or other electronic submission) each of which shall be deemed to be an original and all of which taken together shall
constitute one and the same agreement.

 

		E.	Descriptive Headings. The descriptive headings of this Joinder are inserted for convenience
only and do not constitute a part of this Joinder.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	 	10	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Joinder to the Operating Agreement of TO Pharmaceuticals LLC as of the date set forth in
the introductory paragraph hereof.

 

	 	TO Pharmaceuticals LLC
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 
	 	Holder:
	 	 
	 	 

 

    	 	11Exhibit 10.21

 

THIS WARRANT AND THE SECURITIES ISSUABLE
UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF,
AND MAY NOT BE SOLD, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT AND SUCH STATE SECURITIES LAWS.

 

VOID AFTER 5:00 P.M. ON NOVEMBER 1, 2023

 

TO PHARMACEUTICALS LLC

 

WARRANT TO PURCHASE UNITS

 

New York, New
York

Certificate
No. 3

 

THIS IS TO CERTIFY
THAT, for value received, Bernard Sucher, an individual residing at 715 Sevilla Avenue, Coral Gables, Florida 33134-5627 (the “Warrantholder”),
is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from TO Pharmaceuticals
LLC, a Delaware limited liability (the “Company”), up to 5,594 Class A Units (the “Warrant Units”) of the
Company (“Units”), at an exercise price equal to $45.32 per Unit (the “Exercise Price”) at the times and
in the manner set forth below.

 

As provided herein,
the Exercise Price and the number of Warrant Units which may be purchased upon the exercise of this Warrant are, upon the happening
of certain events, subject to modification and adjustment.

 

The rights of the registered
holder of this Warrant shall be subject to the following further terms and conditions:

 

		1.	Exercise of Warrant; Payment of Exercise Price.

 

		(a)	Exercise of Warrant.

 

(i)       While
this Warrant remains outstanding, this Warrant shall be fully exercisable, in whole or in part, as of the date hereof (the “Exercisability
Date”), upon submission by the Warrantholder to the Company of the exercise form attached as Exhibit A hereto (the
“Exercise Form”) duly executed by the Warrantholder or by the Warrantholder’s duly authorized attorney-in-fact,
at the principal office of the Company, or at such other office or agency in the United States as the Company may designate by
notice in writing to the Warrantholder (in either event, the “Company Offices”), accompanied by payment in accordance
with Section 1(b), of the aggregate Exercise Price payable for the Warrant Units being purchased. If the Warrantholder exercises
the Warrant for fewer than all of the Warrant Units issuable in accordance with this Warrant, the Company shall, upon each exercise
prior to the Expiration Date, execute and deliver to the Warrantholder a new Warrant (dated as of the date hereof) evidencing the
balance of the Units that remain subject to issuance upon the exercise of this Warrant. This Warrant shall expire on the fifth
(5th) anniversary of the date hereof (the “Expiration Date”), and thereupon the Warrantholder shall surrender
this Warrant.

 

    	 	1	 

     

    

  

(ii)       On
the date of exercise of this Warrant, upon the Warrantholder exercising the same in compliance with the terms hereof, and if previous
to such exercise the Warrantholder is not a party to the operating agreement of the Company, upon the execution and delivery to
the Company of the joinder agreement in the form attached hereto as Exhibit B, the Warrantholder shall be deemed to have
become the holder of record for all purposes of the Units to which the exercise relates.

 

(iii)       As
soon as practicable after the exercise of all or part of this Warrant, the Company, at its expense (including the payment by it
of any applicable issue taxes), will cause to be issued in the name of and delivered to the Warrantholder a certificate or certificates
evidencing the number of duly authorized, validly issued, fully paid and nonassessable Units to which the Warrantholder shall be
entitled upon such exercise, if the units of membership interests of the Company are certificated as of such time.

 

(b)          Payment
of Exercise Price. Payment of the Exercise Price shall be made, at the option of the Warrantholder as expressed in the Exercise
Form, by the following methods:

 

(i)        by
delivery to the Company of a certified or official bank check payable to the order of the Company or by wire transfer of immediately
available funds to an account designated in writing by the Company, in the amount of such aggregate Exercise Price for Warrant
Units being purchased hereunder;

 

(ii)       by
instructing the Company to withhold a number of Warrant Units then issuable upon exercise of this Warrant with an aggregate fair
market value (“Fair Market Value”), as determined in good faith by the Board of Managers of the Company as of the Exercise
Date, equal to the aggregate Exercise Price for Warrant Units being purchased hereunder;

 

(iii)      by
surrendering to the Company (x) Warrant Units previously acquired by the Warrantholder with an aggregate Fair Market Value as of
the Exercise Date equal to the aggregate Exercise Price for Warrant Units being purchased hereunder and/or (y) other securities
of the Company having a value as of the Exercise Date equal to the aggregate Exercise Price for Warrant Units being purchased hereunder
(which value in the case of debt securities shall be the principal amount thereof plus accrued and unpaid interest, in the case
of preferred units shall be the liquidation value thereof plus accumulated and unpaid distributions, and in the case of Units shall
be the Fair Market Value thereof); or

 

(iv)      any
combination of the foregoing.

 

In the event of any withholding of Warrant
Units or surrender of other equity securities pursuant to clause (b)(ii) or (iii) above where the number of Units whose value is
equal to the aggregate Exercise Price is not a whole number, the number of Units withheld by or surrendered to the Company shall
be rounded up to the nearest whole Unit and the Company shall make a cash payment to the Warrantholder (by delivery of a certified
or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of a Unit being so
withheld by or surrendered to the Company in an amount equal to the product of (x) such incremental fraction of a Unit being so
withheld or surrendered multiplied by (y) in the case of Units, the Fair Market Value per Warrant Unit as of the Exercise Date,
and, in all other cases, the value thereof as of the Exercise Date determined in accordance with clause (iii)(y) above.

 

    	 	2	 

     

    

  

		2.	Issuance of Units; Reservation of Units.

 

(a)          The
Company covenants and agrees that all Units which may be issued upon the exercise of all or part of this Warrant will, upon issuance
in accordance with the terms hereof, be validly issued and free from all taxes, liens and charges with respect to the issue thereof.

 

(b)          The
Company further covenants and agrees that if any Units to be reserved for the purpose of the issuance of Units upon the exercise
of this Warrant require registration with, or approval of, any governmental authority under any federal or state law before such
Units may be validly issued or delivered upon exercise, then the Company will promptly use its best efforts to effect such registration
or obtain such approval, as the case may be.

 

		3.	Adjustments of Exercise Price, Number and Character
of Warrant Units, and Number of Warrants.

 

The Exercise Price and
the number and kind of securities purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time
upon the happening of the events enumerated in this Section 3.

 

(a)          Distributions,
Subdivisions and Combinations. In case the Company shall at any time on or before the Expiration Date:

 

(i)         pay
or make a distribution in Units or other securities of the Company to holders of all its outstanding Units;

 

(ii)        subdivide
or reclassify the outstanding Units into a greater number of Units;

 

(iii)       combine
the outstanding Units into a smaller number of Units; or

 

(iv)       issue
by reclassification of its Units other securities of the Company (including any such reclassification in connection with a consolidation
or merger in which the Company is the continuing corporation),

 

then the number and kind of securities
purchasable upon exercise of this Warrant outstanding immediately prior thereto shall be adjusted so that the Warrantholder shall
be entitled to receive the kind and number of Units or other securities of the Company which the Warrantholder would have owned
or have been entitled to receive after the happening of any of the events described above had this Warrant been exercised in full
immediately prior to the earlier of the happening of such event or any record date in respect thereto. In the event of any adjustment
of the number of Units or other securities of the Company purchasable upon the exercise of this Warrant pursuant to this Paragraph
3(a), the Exercise Price shall be adjusted to be the amount resulting from dividing the number of Units (including fractional Units)
covered by this Warrant immediately after such adjustment into the total amount payable upon exercise of this Warrant in full immediately
prior to such adjustment. An adjustment made pursuant to this Paragraph 3(a) shall become effective immediately after the effective
date of such event retroactive to the record date for any such event. Such adjustment shall be made successively whenever any event
listed above shall occur.

 

    	 	3	 

     

    

  

(b)          Extraordinary
Distributions.

 

(i)       In
case the Company shall at any time on or before the Expiration Date fix a record date for the issuance of rights, options, or warrants
to all holders of its outstanding Units, entitling them (for a period expiring within 45 days after such record date) to subscribe
for or purchase Units (or securities exchangeable for or convertible into Units) at a price per Unit (or having an exchange or
conversion price per Unit, with respect to a security exchangeable for or convertible into Units) which is lower than the current
Exercise Price per Unit (as defined in Paragraph 3(d) below) on such record date, then the Exercise Price shall be adjusted by
multiplying the Exercise Price in effect immediately prior to such record date by a fraction, of which (i) the numerator shall
be the number of Units outstanding on such record date plus the number of Units which the aggregate offering price of the
total number of Units so to be offered (or the aggregate initial exchange or conversion price of the exchangeable or convertible
securities so to be offered) would purchase at such current Exercise Price and (ii) the denominator shall be the number of Units
outstanding on such record date plus the number of additional Units to be offered for subscription or purchase (or into which the
exchangeable or convertible securities so to be offered are initially exchangeable or convertible). Such adjustment shall become
effective at the close of business on such record date; however, to the extent that Units (or securities exchangeable for or convertible
into Units) are not delivered after the expiration of such rights, options, or warrants, the Exercise Price shall be readjusted
(but only with respect to any portion of this Warrant exercised after such expiration) to the Exercise Price which would then be
in effect had the adjustments made upon the issuance of such rights, options, or warrants been made upon the basis of delivery
of only the number of Units (or securities exchangeable for or convertible into Units) actually issued. In case any subscription
price may be paid in a consideration part or all of which shall be in a form other than cash, the value of such consideration shall
be as determined in good faith by the Board of Managers of the Company and shall be described in a statement mailed to the Warrantholder.
Units owned by or held for the account of the Company shall not be deemed outstanding for the purpose of any such computation.

 

(ii)       In
case the Company shall at any time after the original date of issuance of this Warrant distribute to all holders of its Units (including
any such distribution made in connection with a consolidation or merger in which the Company is the surviving corporation) evidences
of its indebtedness or assets (excluding distributions payable out of consolidated net income or earned surplus in accordance with
New York law and distributions payable in Units described in Paragraph 3(a) above) or rights, options, or warrants or exchangeable
or convertible securities containing the right to subscribe for or purchase Units (or securities exchangeable for or convertible
into Units), then the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record
date for such distribution by a fraction, of which (i) the numerator shall be the current Exercise Price per Unit of the portion
of the evidences of indebtedness or assets so to be distributed or of such rights, options or warrants applicable to one Unit and
(ii) the denominator shall be such current Exercise Price per Unit. Such adjustment shall be made whenever any such distribution
is made, and shall become effective on the date of distribution retroactive to the record date for such transaction.

 

(c)          Minimum
Adjustment. Except as hereinafter provided, no adjustment of the Exercise Price hereunder shall be made if such adjustment
results in a change of the Exercise Price then in effect of less than one dollar ($1.00) per Unit. Any adjustment of less than
one dollar ($1.00) per Unit of any Exercise Price shall be carried forward and shall be made at the time of and together with any
subsequent adjustment which, together with adjustment or adjustments so carried forward, amounts to one dollar ($1.00) per Unit
or more. However, upon exercise of this Warrant, the Company shall make all necessary adjustments (to the nearest cent) not theretofore
made to the Exercise Price up to and including the effective date upon which this Warrant is exercised.

 

    	 	4	 

     

    

  

(d)          Notice
of Adjustments. Whenever the Exercise Price shall be adjusted pursuant to this Section 3, the Company shall promptly deliver
a certificate signed by the Chief Executive Officer, President or a Vice President and by the Chief Financial Officer, Treasurer
or an Assistant Treasurer or the Secretary or an Assistant Secretary of the Company, setting forth, in reasonable detail, the event
requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated (including a description
of the basis on which the Board of Managers of the Company made any determination hereunder), in accordance with the provisions
of Section 8 hereof.

 

(e)          Capital
Reorganizations and Other Reclassifications. In case of any capital reorganization of the Company, or of any reclassification
of the Units (other than a reclassification, subdivision or combination of Units referred to in Paragraph 3(a)), this Warrant shall,
after such capital reorganization, reclassification of Units, consolidation, merger, or sale, be immediately exercisable, upon
the terms and conditions specified in this Warrant, for the kind, amount and number of Units or other securities, assets, or cash
to which a holder of the number of Units purchasable (at the time of such capital reorganization, reclassification of Units, consolidation,
merger or sale) upon exercise of this Warrant would have been entitled to receive upon such capital reorganization, reclassification
of Units, consolidation, merger, or sale; and in any such case, if necessary, the provisions set forth in this Section 3 with respect
to the rights and interests thereafter of the Warrantholder shall be appropriately adjusted so as to be applicable, as nearly equivalent
as possible, to any Units or other securities, assets, or cash thereafter deliverable on the exercise of this Warrant. The Company
shall not effect any such consolidation, merger, or sale, unless prior to or simultaneously with the consummation thereof the successor
corporation or entity (if other than the Company) resulting from such consolidation or merger or the corporation or entity purchasing
such assets or other appropriate corporation or entity shall assume, by written instrument, the obligation to deliver to the Warrantholder
such Units, securities, assets, or cash as, in accordance with the foregoing provisions, such holders may be entitled to purchase
and the other obligations hereunder. The subdivision or combination of Units at any time outstanding into a greater or lesser number
of Units shall not be deemed to be a reclassification of the Units for purposes of this Paragraph 3(f).

 

(f)           Adjustments
to Other Securities. In the event that at any time, as a result of an adjustment made pursuant to this Section 3, the Warrantholder
shall become entitled to purchase any Units or securities of the Company other than the Units, thereafter the number of such other
Units or securities so purchasable upon exercise of each Warrant and the exercise price for such Units or securities shall be subject
to adjustment from time to time in a manner and on terms as nearly equivalent as possible to the provisions with respect to the
Units contained in Paragraphs 3(a) through (c), inclusive.

 

(g)          Deferral
of Issuance of Additional Units in Certain Circumstances. In any case in which this Section 3 shall require that an adjustment
in the Exercise Price be made effective as of a record date for a specified event, the Company may elect to defer until the occurrence
of such event issuing to the Warrantholder exercised after such record date the Units, if any, issuable upon such exercise over
and above the Units, if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such adjustment;
provided, however, that the Company shall deliver as soon as practicable to such holder a due bill or other appropriate
instrument provided by the Company evidencing such holder’s right to receive such additional Units upon the occurrence of
the event requiring such adjustment.

 

    	 	5	 

     

    

  

4.             Replacement
of Securities. If this Warrant shall be lost, stolen, mutilated or destroyed, the Company shall, on such terms as to indemnity
or otherwise as the Company may in its discretion reasonably impose, issue a new warrant of like tenor or date representing in
the aggregate the right to subscribe for and purchase the number of Units which may be subscribed for and purchased hereunder.
Any such new warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen,
mutilated or destroyed warrant shall be at any time enforceable by anyone.

 

5.             Registration.
This Warrant shall be numbered and shall be registered in a register (the “Warrant Register”) maintained at the offices
of the Company as they are issued. The Warrant Register shall list the name, address and Social Security or other Federal Identification
Number, if any, of all warrantholders. The Company shall be entitled to treat the Warrantholder as set forth in the Warrant Register
as the owner in fact of this Warrant as set forth therein for all purposes and shall not be bound to recognize any equitable or
other claim to or interest in this Warrant on the part of any other person, and shall not be liable for any registration or transfer
of this Warrant that is registered or to be registered in the name of a fiduciary or the nominee of a fiduciary unless made with
the actual knowledge that a fiduciary or nominee is committing a breach of trust in requesting such registration of transfer, or
with such knowledge of such facts that its participation therein amounts to bad faith.

 

6.             Transfer.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED. THIS WARRANT HAS BEEN ACQUIRED, AND ANY UNITS OR ANY OTHER SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT
ARE REQUIRED TO BE ACQUIRED, FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE SOLD, ASSIGNED,
PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR THIS WARRANT AND/OR SUCH UNITS OR
OTHER SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY
TO THE ISSUER OF THIS WARRANT AND SUCH UNITS OR OTHER SECURITIES TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT
AND SUCH STATE SECURITIES LAWS.

 

7.             Exchange
of Warrant. This Warrant may be exchanged for another warrant entitling the Warrantholder thereof to purchase a like aggregate
number of Units as this Warrant entitles such Warrantholder to purchase. A Warrantholder desiring to so exchange this Warrant shall
make such request in writing delivered to the Company, and shall surrender this Warrant therewith. Thereupon, the Company shall
execute and deliver to the person entitled thereto a new warrant or warrants, as the case may be, as so requested.

 

8.             Notices.
All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified
mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed:

 

If to the
Company:

 

TO PHARMACEUTICALS
LLC

77 Water
Street, 8th Floor

New York,
New York 10005

Email: seth@katanassociates.com

Attention:
CEO

 

    	 	6	 

     

    

  

With a copy
to:

 

Kaufman &
Associates, LLC

190 Motor
Parkway, Suite 202

Hauppauge,
New York 11788

Telephone:
(631) 972-0042

Facsimile:
(631) 410-1007

Attention:
Neil M. Kaufman

Email: nkaufman@kaufman-associates.com

 

If to the
Warrantholder:

 

Bernard Sucher

715 Sevilla
Avenue

Coral Gables,
Florida 33134-5627

Email: bernie@tikunolam.com

 

Each such notice or other communication
shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger
or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying
next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of
its receipt or five (5) days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United
States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer, if
sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s
next business day, or (iv) if sent via electronic mail, upon its delivery, if sent during normal business hours of the recipient,
or if not sent during normal business hours of the recipient, then on the recipient’s next business day.

 

9.             Miscellaneous.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination is sought. This Warrant is deemed to have been
delivered in the State of New York and shall be construed and enforced in accordance with and governed by the laws of such State,
without regard to its conflicts of laws principles. The headings in this Warrant are for purposes of reference only, and shall
not limit or otherwise affect any of the terms hereof.

 

10.          Expiration.
Unless as hereinafter provided, the right to exercise this Warrant shall expire at the Expiration Date.

 

[Signature Page Follows]

 

    	 	7	 

     

    

 

Dated: November 1, 2018

 

	 	TO PHARMACEUTICALS LLC
	 	 	 
	 	By:	/s/ Seth Yakatan
	 	 	Seth Yakatan
	 	 	Chief Executive Officer

 

    	 	8	 

     

    

 

EXHIBIT A

EXERCISE FORM

 

	 	Dated:___________________________

 

TO: TO PHARMACEUTICALS LLC:

 

The undersigned hereby
irrevocably elects to exercise the within Warrant, to the extent of purchasing _____________ Units, and hereby makes payment of
the Exercise Price in payment of the actual Exercise Price therefor as follows:

 

 ̈$___________________
by certified or official bank check payable to the order of the Company or by wire transfer.

 

 ̈$________________
by withholding Warrant Units issuable upon exercise of this Warrant;

 

 ̈$_____________
by surrendering to the Company (x) $__________ for Warrant Units previously acquired by the Warrantholder, and/or (y)$_______for
other securities of the Company.

 

INSTRUCTIONS FOR REGISTRATION OF UNITS

 

	Name:	 	 
	 	 	(Please type or print in block letters)
	 	 	 
	Taxpayer Identification Number:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Signature:	 	 
	 	 	(Signature must conform in all respects to the name of the Warrantholder as set forth on the face of this Warrant)

 

    	 	9	 

     

    

 

EXHIBIT B

JOINDER TO 

 

OPERATING AGREEMENT

 

This JOINDER
(the “Joinder”) to the Amended and Restated Operating Agreement of TO Pharmaceuticals LLC, a Delaware limited
liability company (the “Company”), dated as of July 13, 2018, as amended or restated from time to time (the
“Agreement”), is made and entered into as of the date below, by and between the Company and the undersigned
(“Holder”). Capitalized terms used herein but not otherwise defined shall have the meanings set forth in the
Agreement.

 

WHEREAS, on
the date hereof, Holder has acquired ______ Class A Units and the Agreement and the Company require Holder, as a holder of such
Interest, to become a party to the Agreement, and Holder agrees to do so in accordance with the terms hereof.

 

NOW, THEREFORE,
in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties to this Joinder hereby agree as follows:

 

		A.	Agreement to be Bound. Holder hereby (i) acknowledges that he/she/it has
                                                                received and reviewed a complete copy of the Agreement and (ii) agrees that upon execution of this Joinder, he/she/it shall
                                                                become a party to the Agreement and shall be fully bound by, and subject to, all of the covenants, terms and conditions of
                                                                the Agreement as though an original party thereto and shall be deemed, and is hereby admitted as, a Member for all purposes
                                                                thereof and entitled to all the rights incidental thereto.

 

		B.	Members Schedule. For purposes of Exhibit A to the Agreement, the name, address,
capital account, Allocation Percentages and number of Membership Units of the Holder are as follows:

 

	Name of Member	 	Capital	 	Allocation	 	 	Membership	 
	and Address	 	Account	 	Percentage	 	 	Units	 
	[________________]	 	$	________	 	__	%	 	[_____]	 

 

		C.	Governing Law. This Agreement and the rights of the parties hereunder shall be interpreted
in accordance with the laws of the State of Delaware, and all rights and remedies shall be governed by such laws without regard
to principles of conflicts of laws.

 

		D.	Counterparts. This Joinder may be executed in multiple counterparts (and may be transmitted
via facsimile or other electronic submission) each of which shall be deemed to be an original and all of which taken together shall
constitute one and the same agreement.

 

		E.	Descriptive Headings. The descriptive headings of this Joinder are inserted for convenience
only and do not constitute a part of this Joinder.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	 	10	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Joinder to the Operating Agreement of TO Pharmaceuticals LLC as of the date set forth in
the introductory paragraph hereof.

 

	 	TO Pharmaceuticals LLC
	 	 	 
	 	By:	     
	 	 	Name:
	 	 	Title:
	 	 
	 	Holder:
	 	 
	 	 

 

    	 	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]